June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Real-world data on intravitreal Aflibercept (Eylea) injection in patients with wet age-related macular degeneration
Author Affiliations & Notes
  • javid suleman
    Ophthalmology, James Cook University Hospital, Stockton on tees, United Kingdom
  • Darren Ting
    Ophthalmology, James Cook University Hospital, Stockton on tees, United Kingdom
  • Philip Stephen Severn
    Ophthalmology, James Cook University Hospital, Stockton on tees, United Kingdom
  • Sreekumari Pushpoth
    Ophthalmology, James Cook University Hospital, Stockton on tees, United Kingdom
  • Footnotes
    Commercial Relationships javid suleman, None; Darren Ting, None; Philip Severn, None; Sreekumari Pushpoth, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4610. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      javid suleman, Darren Ting, Philip Stephen Severn, Sreekumari Pushpoth; Real-world data on intravitreal Aflibercept (Eylea) injection in patients with wet age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4610.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To report the functional and structural outcomes, and safety of intravitreal Aflibercept (Eylea) injection in patients with wet age-related macular degeneration (AMD).

 
Methods
 

This was a retrospective, non-comparative, interventional case series. All the patients who received intravitreal Aflibercept injection for wet AMD between July 2013 and July 2014 (1-year period) were included in this study. Patients’ clinical notes were reviewed for relevant data, including demographic factors, best-corrected visual acuity (BCVA) and central macular thickness (CMT) on optical coherence topography (OCT) at baseline, post-loading dose (3 sequential monthly injections), 6th month and 12th month, fundus fluorescein angiogram findings, pre-treatment ocular co-morbidities and complications during the treatment period.

 
Results
 

During the study period, a total of 350 patients were identified. The mean age was 79.9 ± 8.4 years with a male:female ratio of 0.85. The mean follow-up period 8.7 ± 3.9 months. The mean baseline BCVA was 52.6 ±16.5 letters. There was a mean gain of 0.2 letters at post-loading phase (p=0.980), 6.4 letters at 6th month (p=0.487), and 6.3 letters at 12th month (p=0.595). The mean baseline CMT was 329 ± 97 µm and improved to 244 ± 90 µm at post-loading phase (p=0.002), 225 ± 51 µm at 6th month (p<0.001), and 223 ± 71 µm at 12th month (p=0.031). No complication was noted during the study period except for a case of retinal pigment epithelial (RPE) rip.

 
Conclusions
 

Our study demonstrates the efficacy and safety of intravitreal Aflibercept injection in patients with wet AMD in a real-world setting. Our data parallels the outcome reported in VIEW 1 and VIEW 2 studies.

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×